RENAL CELL CARCINOMA

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This study tests whether giving two drugs (pembrolizumab and axitinib) before surgery can shrink tumor clots in the main vein (inferior vena cava) for people with kidney cancer. About 17 adults with clear cell kidney cancer and a vein clot will receive the drugs for 12 weeks, the…

This study tests a new drug, BMS-986506, for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to other treatments. The main goal is to check if the drug is safe and tolerable. About 125 adults who have already tried at least tw…

This study tests whether using a PET scan to guide radiation therapy can better control lung cancer, melanoma, or kidney cancer that has started growing again in up to 5 spots. About 32 adults will receive either standard radiation or a PET-adapted version that delivers a higher …

This study is testing whether combining two drugs, envafolimab and lenvatinib, can shrink tumors in people with advanced solid tumors (like lung, kidney, or liver cancer) who have run out of standard options. About 170 adults will receive the combination to find the best dose and…

This study tests whether a combination of three drugs (sasanlimab, palbociclib, and axitinib) can shrink tumors in people with advanced kidney cancer that has spread. About 25 adults with clear cell or translocation renal cell carcinoma will receive the drugs and be monitored for…

This study looks at whether a blood test that detects leftover cancer DNA can help decide who needs additional treatment after kidney cancer surgery. About 100 people with high-risk clear cell kidney cancer will join. Those with no detectable cancer DNA will skip standard immunot…

This study is testing a high-precision radiation treatment called SBRT for people with kidney cancer that cannot be removed with surgery. About 70 adults with newly diagnosed or recurrent kidney tumors will receive this targeted radiation. The main goal is to see how well it cont…

This study is for people with advanced kidney cancer (clear cell type) that came back during or within 2 years after finishing a type of immunotherapy called anti-PD-(L)1. Researchers are testing several new combinations of drugs to see if they are safe and can shrink tumors. Abo…

This early-phase trial tests a new treatment called VET3-TGI, a virus designed to infect and kill cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatments. The main go…

This study tests a combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose tumors grew despite prior immunotherapy. The goal is to find the safest dose of ruxolitinib and see if the combo can shrink tumors. About 40 participants…

This early-phase study tests a new drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check …

This study tests the drug olaparib (a pill) in 20 people with advanced kidney cancer that has spread. To join, your tumor must have a specific gene mutation (like BAP-1 or BRCA). The goal is to see if the drug can shrink or stop tumor growth for at least 6 months. Participants mu…

This study tests whether giving a combination of two drugs (axitinib and a PD-1 inhibitor) before surgery can help prevent kidney cancer from coming back in patients at high risk of recurrence. About 298 participants will be randomly assigned to receive either the drug combo foll…

This study tests a drug called alectinib, already approved for some lung cancers, in people with other rare cancers that have a specific gene change (ALK). About 30 adults, teens, and children will receive the drug to see if it shrinks tumors or stops cancer growth for at least 2…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people whose non-small cell lung cancer, melanoma, or kidney cancer has been surgically removed. The goal is to see how the body processes HLX17 compared to Keytruda, and to check fo…

This study tests whether a higher dose of the drug cabozantinib can help people with advanced kidney cancer whose disease got worse while on the standard dose. About 18 adults whose cancer had been controlled by cabozantinib for at least 6 months will receive an increased dose. T…

This study tests whether a combination of two drugs, tivozanib and nivolumab, can help control advanced non-clear cell kidney cancer. About 48 adults with this rare type of kidney cancer will receive the treatment. The goal is to see if the combo is safe and effective at shrinkin…

This study looks at how well the drug T-DXd works for people with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. About 100 adults in the US will be followed to see if their tumors shrink or stop growing. The goal is to u…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This early-stage study tests an experimental drug (HC-7366) alone and with an approved targeted therapy (belzutifan) in about 80 adults with advanced kidney cancer that cannot be removed by surgery or has spread. The main goal is to find the safest dose and check for side effects…

This study tests whether the drug casdatifan, alone or with zimberelimab, can safely shrink kidney tumors before surgery. It is for adults with a specific type of kidney cancer (clear cell renal cell carcinoma) that is large or has spread. The goal is to see if the treatment redu…

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare genetic condition (HLRCC) or sporadic papillary kidney cancer. The drugs work by cutting off the tumor's blood suppl…

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before kidney cancer surgery is safe and practical. Ten adults with locally advanced clear cell kidney cancer will receive the drugs before their planned nephrectomy. Researchers will check if the …

This study tests if kidneys that have a small tumor can be safely donated and repaired outside the body, then transplanted into people with kidney failure. The goal is to increase the number of available donor kidneys. The study will check for serious side effects within 30 days …

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few new cancer spots in patients with metastatic kidney cancer who are already on immunotherapy. About 30 adults will receive radiation to up to 5 growing tumors while continuing their c…

This study is testing a special type of radiotherapy for people with kidney cancer that got worse after immunotherapy. The goal is to see if this treatment can control the cancer and how safe it is. About 35 adults will take part, and their tumors will be checked regularly for up…

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This early-phase study tests a new drug, QXL138AM, for safety and tolerability in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. Participants must have tried standard treatments without success. The study will also look…

This study tests if cooling the kidney with ice slush during robot-assisted partial nephrectomy helps it recover from temporary blood flow loss. About 310 adults with kidney cancer will be randomly assigned to receive cold or warm ischemia. The goal is to see if cold preservation…

This study tests whether giving the drugs pembrolizumab alone or with lenvatinib before and after kidney cancer surgery can boost the immune system's ability to fight the cancer. About 30 adults with high-risk kidney cancer will take part. Researchers will measure changes in immu…

This early-phase study tests a new drug called NEO-811 in about 30 people with advanced clear cell kidney cancer that cannot be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants must have tried or refused standard treatments.

This early-stage study tests a new oral drug, DCC-2812, in about 60 people with advanced kidney, bladder, or prostate cancer that has spread or not responded to other treatments. The main goals are to check safety and find the right dose, while also watching for any tumor shrinka…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests whether a combination of two drugs (belzutifan and zanzalintinib) works better than the standard drug cabozantinib for people with advanced kidney cancer that came back after previous treatment. About 904 participants will be randomly assigned to one of the two t…

This study tests whether a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) can stop or slow the growth of kidney cancer that has spread to the brain. About 20 adults with untreated brain metastases will receive the drugs. The goal is to see if this approach i…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study is for people with kidney cancer who cannot have surgery or other local treatments. It uses a precise type of radiation called proton beam therapy to target the tumor while aiming to protect the kidney. Researchers will track how well the kidney works after treatment a…

This study tests whether a special ultrasound (contrast-enhanced ultrasound, or CEUS) can better detect kidney cancer that has come back after a tumor-freezing or heat-based treatment (ablation). About 210 adults who had this treatment will get both standard scans and CEUS. The g…

This study explores whether new types of PET scans can more accurately detect and stage kidney cancer (renal cell carcinoma). Researchers will test three different imaging agents in 66 adults with suspected or confirmed kidney cancer, as well as healthy volunteers. The goal is to…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study tests whether giving the cancer drug nivolumab as a shot at home is as safe and effective as getting it in a clinic. About 50 adults with various cancers will try both settings to see which they prefer and how it affects their quality of life. The goal is to reduce the…

This study tests whether giving cancer treatment at home is preferred over going to a clinic. It involves 27 adults with various cancers in the Florida Panhandle. The goal is to see if home care improves patient satisfaction and is safe.

This study looks at how often a specific gene change (BAP1 mutation) occurs in people with certain cancers like eye melanoma, skin melanoma, kidney cancer, and others. Researchers will study 500 patients and their family members to understand cancer patterns and risk factors. The…

This study tests a special PET/CT scan that may help doctors see kidney cancer more clearly. It is not a treatment—its goal is to learn how well the scan shows cancer activity. About 35 adults with kidney cancer will take part. The scan results will be compared with tissue sample…

This study is a registry that collects information from about 1,930 people with advanced kidney or bladder cancer in Germany. Researchers will track what treatments patients receive, how their disease responds, and their quality of life over time. The goal is to understand real-w…

This study tests whether a combined PET/MR scan can better tell aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will get one extra scan during their routine MRI. The goal is to reduce unnecessary surgeries by improving…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already receiving immunotherapy. Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in immune cells in the blood ca…

This study aims to learn more about kidney and urinary tract cancers that run in families. Researchers will follow up to 5,000 people with or at risk for these inherited conditions, collecting blood, tissue, and urine samples over time. The goal is to identify new genes linked to…

This study looks at whether a blood test that detects tiny bits of tumor DNA can help monitor kidney cancer after surgery. Researchers will follow 450 people with newly diagnosed kidney cancer who have surgery to remove the tumor. The goal is to see if this test can predict cance…

This study tests a small implantable device that releases tiny amounts of 19 different cancer drugs directly into a kidney tumor. The goal is to see if the device is safe and can help doctors figure out which drug works best for each patient. About 20 adults with kidney cancer wh…

This study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. About 600 adults having surgery or a biopsy will receive a special nutrient tracer through an IV. Blood and tissue samples are then analyzed to see how the cancer uses these fuels. Partic…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…